Genetic polymorphisms of RAD51 and XRCC3 and acute myeloid leukemia risk: a meta-analysis. Issue 6 (June 2014)

• Record Type: Journal Article
• Authors: Li, Cuiping; Liu, Yun; Hu, Zhen; Zhou, Yang
• Is Part Of: Leukemia & lymphoma. Volume 55:Issue 6(2014:Jun.)
• Page Start: 1309
• Page End: 1319
• Publication Date: 2014-06
• Subjects: Leukemia -- Periodicals; Lymphomas -- Periodicals; 616.99419
• DOI: 10.3109/10428194.2013.835404
• Languages: English
• ISSNs: 1042-8194

Abstract

<abstract> <title>Abstract</title> <p>Studies on gene polymorphisms of <italic>RAD51</italic> and X-ray repair cross-complementing group 3 (<italic>XRCC3</italic>) and acute myeloid leukemia risk (AML) are conflicting and there is no recent meta-analysis. Therefore, the purpose of this study was to evaluate the effect of <italic>RAD51</italic> G135C and <italic>XRCC3</italic> Thr241Met genotypes on AML susceptibility. We conducted a systematic search of three databases including PubMed and EMBASE for the period up to 20 February 2013 and identified 43 relevant studies. Six eligible studies were eventually selected for <italic>RAD51</italic> (1764 cases and 3469 controls) and six studies for <italic>XRCC3</italic> (1352 cases and 2582 controls). Pooled odds ratios (ORs) and 95% confidence intervals (CIs) for the risk of AML associated with <italic>RAD51</italic> and <italic>XRCC3</italic> were appropriately calculated based on fixed- or random-effects models. The quality of studies was evaluated using the Newcastle-Ottawa Scale (NOS). Subgroup analyses were performed among Asian, Caucasian and other populations. The pooled results showed that the leukemia risk was not significantly associated with <italic>RAD51</italic>: the same results were obtained among any subgroup analysis. No significant association was demonstrated for AML risk with <italic>XRCC3</italic> in the total population, but elevated associations were observed in Caucasians for the homozygote and recessive comparison (Met/Met vs. Thr/Thr, OR = 1.67, 95% CI = 1.09–2.57, <italic>p</italic> = 0.019; recessive model, OR = 1.78, 95% CI = 1.19–2.65, <italic>p</italic> = 0.005). This meta-analysis provides evidence that the <italic>RAD51</italic> and <italic>XRCC3</italic> polymorphisms are not associated with an increased risk of AML in the total population.</p> </abstract>